begins

Dosing begins with a trial of a new immunotherapy for the treatment of advanced solid tumors

A phase 1a/1b, first-in-human study of a new immunotherapy agent, AB248, has given the agent to the first patient with a locally advanced or metastatic solid tumor. The first patient received a dose of a new therapy, AB248, as part of AB248-011 (NCT05653882) a phase 1a/1b study of immunotherapy in combination with pembrolizumab (Keytruda) for …

Dosing begins with a trial of a new immunotherapy for the treatment of advanced solid tumors Read More »

Treatment with the new KRAS inhibitor begins in the phase 1/1B study, COVALENT-10

The COVALENT-102 study initiated BMF-219 treatment in patients with KRAS-mutated, advanced solid tumors. The first patient with KRAS– mutated, inoperable, locally advanced or metastatic solid tumor was dosed with BMF-219, signaling the start of treatment in the phase 1/1b study COVALENT-102 (NCT05631574).1 BMF-219 is a pan-KRAS targeting inhibitor KRAS G12C, G12D, G12R and others KRAS …

Treatment with the new KRAS inhibitor begins in the phase 1/1B study, COVALENT-10 Read More »